Prospective, Comparative, Randomized, Controlled Trial on the Efficacy of the Treatment of Gastroesophageal Reflux Infant With Magnesium Alginate

Federico II University

Status: Unknown

Conditions: Vomiting; Gastroesophageal Reflux; Regurgitation; Chronic Cough

Treatments: Dietary Supplement: thickened milk; Drug: Gastrotuss

Study type: Interventional

Funder types: Other

Identifiers

NCT01858584

STDMG2013

Details and patient eligibility

About

The results on the efficacy of the formulations based on alginic acid are controversial. Corvaglia et al demonstrated a significant reduction in reflux episodes in preterm infants by evaluation with pH-impedance analysis. This study concludes that the use of alginic acid reduces the acidity of the gastroesophageal reflux (GER) and has a non-systemic effect and a lesser presence of side effects compared to the use of H2-receptor antagonist(H2RA) and proton pump inhibitor (PPI).

Full description

Primary outcomes This prospective, randomized, controlled trial aims to determine, in a population of infants within one year of life, suffering from gastroesophageal reflux (GER) the effectiveness of magnesium alginate. The clinical improvement of the patient will be evaluated based on the negativity of the symptom score (4.3.1), assessed using a validated questionnaire on symptoms of GER (I-GERQ Annex A).

Secondary outcomes To compare the efficacy of Magnesium Alginate on GER in infants compared with those of thickened feeding and reassurance, basing on questionnaire results.

Enrollment: 75 estimated patients

Sex: All

Ages: Under 12 months old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age < 1 year
• Suggestive symptoms of gastroesophageal reflux (I-GERQ score > 7)
• Absence of clinical evidence of allergy to cow milk protein or other allergic disorder
• No previous intake of thickened formulas, acid suppressants or drugs
• All parents or guardians must sign a document of informed consent
• Patients affected by chronic disease
• Patients affected by hepatic or renal diseases
• Patients affected by cardiac diseases

Exclusion criteria

• Patients affected by chronic disease
• Patients affected by hepatic or renal diseases
• Patients affected by cardiac diseases
• Inability or unwillingness to give informed consent
• Patients wth severe neurologic disease
• Patients affected by cow milk protein allergy
• Previous or ongoing intake of thickened formulas, acid suppressants or drugs

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

75 participants in 3 patient groups

Gastrotuss

Experimental group

Description:

Gastrotuss baby: syrup based on alginate consisting of: magnesium alginate, simethicone, fructose, xanthan gum, honey, D-panthenol, fluid extracts of Althaea officinalis, Papaver rhoeas, zinc oxide, sodium bicarbonate, sodium hydroxide, p-hydroxybenzoate of methyl-sodium, sodium propyl p-hydroxybenzoate, natural flavors, erythrosine (E127), purified water. dosage: * Infants weighing \<5 kg in 2.5 ml 5-10 min after feeding. In case of regurgitation after administration, 1 ml additional * Infants weighing\> 5 kg per 5 ml dose after the meal and the evening before putting the baby to sleep The administration should be maximum 3 times per day

Treatment:

Drug: Gastrotuss

Thickened Formula

Active Comparator group

Description:

Milk thickened (formulat AR): contains a special thickener derived from corn starch waxy, that maintains its fluidity into the bottle and thickens just inside the stomach of the child, and this makes it easy to use in breastfeeding , as it is usable with a common teat.

Treatment:

Dietary Supplement: thickened milk

control group

No Intervention group